EP Patent

EP1905434A1 — Organic compounds comprising an S1P receptor agonist and their therapeutic use

Assigned to Novartis AG · Expires 2008-04-02 · 18y expired

What this patent protects

The present invention provides a solid pharmaceutical composition suitable for oral administration, comprising an S1P receptor agonist in the absence of a sugar alcohol.

USPTO Abstract

The present invention provides a solid pharmaceutical composition suitable for oral administration, comprising an S1P receptor agonist in the absence of a sugar alcohol.

Drugs covered by this patent

fingolimod-hydrochloride (FINGOLIMOD HYDROCHLORIDE)

Patent Metadata

Patent number: EP1905434A1
Jurisdiction: EP
Classification: —
Expires: 2008-04-02
Drug substance claim: No
Drug product claim: No
Assignee: Novartis AG
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.